KURA Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

81.55M

+51.34%

-0.109

-50.5%

87.18M

+517.91%

-0.790

+19.7%

-0.812

+8.27%

Estimates Revision

The market is revising Downward the revenue expectations for Kura Oncology, Inc. (KURA) for FY2025, with the revenue forecasts being adjusted by -12.53% over the past three months. During the same period, the stock price has changed by -6.83%.

Revenue Estimates for FY2025

Revise Downward

-12.53%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+4.76%

In Past 3 Month

Stock Price

Go Down

-6.83%

In Past 3 Month

12 Analyst Rating

Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 26.88 USD with a low forecast of 11.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

11.00

Averages

26.88

High

40.00

Current: 0.000

Low

11.00

Averages

26.88

High

40.00

Barclays

Etzer Darout

Overweight

maintain

$11 -> $28

2025-11-24

Reason

Barclays

Etzer Darout

Price Target

$11 -> $28

2025-11-24

maintain

Overweight

Reason

Barclays analyst Etzer Darout raised the firm's price target on Kura Oncology to $28 from $11 and keeps an Overweight rating on the shares. The firm cites the ziftomenib approval for the target increase.

UBS

David Dai

Buy

maintain

$14 -> $16

2025-11-14

Reason

UBS

David Dai

Price Target

$14 -> $16

2025-11-14

maintain

Buy

Reason

UBS analyst David Dai raised the firm's price target on Kura Oncology to $16 from $14 and keeps a Buy rating on the shares.

Wedbush

Outperform

maintain

$36 -> $38

2025-11-14

Reason

Wedbush

Price Target

$36 -> $38

2025-11-14

maintain

Outperform

Reason

Wedbush raised the firm's price target on Kura Oncology to $38 from $36 and keeps an Outperform rating on the shares. The firm notes Ziftomenib at 600 mg QD dosing was approved in r/r NPM1m AML, ahead of the PDUFA date of November 30th. The approval was based on the KOMET-001 study.

BofA

Jason Zemansky

Buy

maintain

$29 -> $30

2025-11-14

Reason

BofA

Jason Zemansky

Price Target

$29 -> $30

2025-11-14

maintain

Buy

Reason

BofA analyst Jason Zemansky raised the firm's price target on Kura Oncology to $30 from $29 and keeps a Buy rating on the shares. The FDA approval of Kura's ziftomenib as "Komzifti" is "a watershed moment for the company," the analyst tells investors. Following the update, the firm increased odds of success for Komzifti approval to 100% while also adjusting sales to reflect about one month for Komzifti to roll out, driving its revised target.

Guggenheim

Neutral

initiated

2025-09-04

Reason

Guggenheim

Price Target

2025-09-04

initiated

Neutral

Reason

Guggenheim initiated coverage of Kura Oncology (KURA) with a Neutral rating and no price target. The firm expects a near-term relapsed/refractory nucleophosmin 1-mutated acute myeloid leukemia launch for the company buy says it will be difficult to drive value with Syndax (SNDX_ already on market for this smaller patient population.

Guggenheim

Brad Canino

Neutral

initiated

2025-09-03

Reason

Guggenheim

Brad Canino

Price Target

2025-09-03

initiated

Neutral

Reason

Guggenheim analyst Brad Canino initiated coverage of Kura Oncology with a Neutral rating.

Valuation Metrics

The current forward P/E ratio for Kura Oncology Inc (KURA.O) is -4.11, compared to its 5-year average forward P/E of -6.57. For a more detailed relative valuation and DCF analysis to assess Kura Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.57

Current PE

-4.11

Overvalued PE

-3.61

Undervalued PE

-9.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.16

Current EV/EBITDA

-1.40

Overvalued EV/EBITDA

-0.49

Undervalued EV/EBITDA

-5.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.12

Current PS

3.91

Overvalued PS

3.74

Undervalued PS

-1.49

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

KURA News & Events

Events Timeline

No data

News

2.0

2025-12-22SeekingAlpha

Kura Oncology Gains Ground After Jim Cramer's Remarks

2.0

2025-12-22NASDAQ.COM

After-Hours Gains on Friday: Biotech and Genomics Stocks Demonstrate Resilience

9.0

2025-12-08Newsfilter

Kura Oncology Reports 86% CR Rate for KOMZIFTI in AML Treatment

People Also Watch

Frequently Asked Questions

What is Kura Oncology Inc (KURA) stock price today?

The current price of KURA is 9.55 USD — it has increased 0 % in the last trading day.

What is Kura Oncology Inc (KURA)'s business?

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

What is the price predicton of KURA Stock?

What is Kura Oncology Inc (KURA)'s revenue for the last quarter?

Kura Oncology Inc revenue for the last quarter amounts to 20.75M USD, decreased % YoY.

What is Kura Oncology Inc (KURA)'s earnings per share (EPS) for the last quarter?

Kura Oncology Inc. EPS for the last quarter amounts to -0.85 USD, increased 34.92 % YoY.

What changes have occurred in the market's expectations for Kura Oncology Inc (KURA)'s fundamentals?

How many employees does Kura Oncology Inc (KURA). have?

Kura Oncology Inc (KURA) has 192 emplpoyees as of January 09 2026.

What is Kura Oncology Inc (KURA) market cap?

Today KURA has the market capitalization of 831.02M USD.